Lytix Biopharma AS
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
- Conditions
- Advanced Melanoma
- Interventions
- Combination Product: LTX-315 in combination with pembrolizumab
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 20
- Registration Number
- NCT04796194
- Locations
- 🇺🇸
Levine Cancer Institute - Atrium Health, Charlotte, North Carolina, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇳🇴Oslo University Hospital--Radiumhospitalet, Oslo, Norway
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Combination Product: LTX-315 and TILs
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 6
- Registration Number
- NCT03725605
- Locations
- 🇩🇰
Herlev Hospital, Copenhagen, Denmark
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
- Conditions
- CancerMelanomaBreast CancerHead and Neck CancerLymphomaTriple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 80
- Registration Number
- NCT01986426
- Locations
- 🇳🇴
Oslo University Hospital Radiumhospitalet, Oslo, Norway
🇮🇹Intotuto Europeo di Oncologia (IEO), Milano, Italy
🇮🇹San Raffaele Hospital, Milano, Italy
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
- Conditions
- Non-bullous Impetigo
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 210
- Registration Number
- NCT01803035
- Locations
- 🇩🇴
Institute of Dermatology and and Skin Surgery Dr. Hubert Bogaert Diaz, Santo Domingo, Dominican Republic
🇩🇴Dr. Robert Reid Cabral Children Hospital, Santo Domingo, Dominican Republic
A Study to Evaluate Safety, Tolerability and Efficacy of Lytixarâ„¢ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection
- Conditions
- Gram-positive, Skin InfectionsMild Eczema/DermatosesAtopic Dermatitis
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2011-02-16
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 24
- Registration Number
- NCT01223222
- Locations
- ðŸ‡ðŸ‡º
Debreceni Egyetem Orvos-és Egészségtudományi, Debrecen, Hungary
ðŸ‡ðŸ‡ºPécsi Tudományegyetem általános Orvostudom´nyi Centum, Pécs, Hungary
ðŸ‡ðŸ‡ºMiskolci Semmelweis Ignác Egészegügyi Központ és, Miskolc, Hungary
A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 12
- Registration Number
- NCT01223209
- Locations
- 🇳🇴
University Hospital North-Norway, Tromsø, Norway
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 24
- Registration Number
- NCT01158235
- Locations
- 🇸🇪
Skåne University Hospital, Malmö, Sweden
Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour
- Conditions
- Cancer With Transdermal Accessible Tumour
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 14
- Registration Number
- NCT01058616
- Locations
- 🇳🇴
Oslo University Hospital, Radiumhospitalet, Oslo, Norway
🇸🇪Karolinska University Hospital, Solna, Stockholm, Sweden